Clinical trials evaluating the combination of BTK or BCL-2 inhibitors with ROR1-targeting therapies have yielded encouraging results, further underscoring the critical role of ROR1 in cancer progression and therapy resistance. This evidence concerns the gene BCL2 and cancer.